I'd say that's precisely what we're striving to do, to have a more coordinated approach to post-market surveillance activity, and as Dr. Turner was mentioning, that's a combination of increasing reporting of serious adverse drug reactions, but also doing things like working with data sets that exist at provincial and territorial levels, data sets that the Canadian Patient Safety Institute is developing, and data sets that CADTH, the drug and health technology assessment agency, has. So it's a combination of recording and data coming in, but also proactively mining data sources that exist. That's how you can get a better and more complete picture of what's taking place out there.
On January 31st, 2008. See this statement in context.